Targeting the LY6H-PI3K/AKT autophagy axis suppresses HCC malignancy and reveals a druggable vulnerability - PubMed
5 hours ago
- #Autophagy
- #LY6H
- #Hepatocellular Carcinoma
- LY6H is upregulated in hepatocellular carcinoma (HCC) and correlates with poor patient survival.
- LY6H binds to the p85 subunit of PI3K, stabilizes its phosphorylation, and activates the PI3K/AKT pathway to drive autophagy.
- LY6H promotes HCC cell proliferation through the PI3K/AKT-autophagy axis, which can be suppressed by the PI3K inhibitor LY294002.
- NSC243928 is identified as a small-molecule inhibitor of LY6H, blocking autophagy and tumor-promoting effects in vitro and in vivo.
- Positive correlations exist among LY6H, ATG3, Beclin1, PI3K, and AKT in HCC tissues, and their co-overexpression indicates worse prognosis.